Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9825789rdf:typepubmed:Citationlld:pubmed
pubmed-article:9825789lifeskim:mentionsumls-concept:C0019682lld:lifeskim
pubmed-article:9825789lifeskim:mentionsumls-concept:C0019163lld:lifeskim
pubmed-article:9825789lifeskim:mentionsumls-concept:C0019699lld:lifeskim
pubmed-article:9825789lifeskim:mentionsumls-concept:C0021311lld:lifeskim
pubmed-article:9825789lifeskim:mentionsumls-concept:C0237401lld:lifeskim
pubmed-article:9825789lifeskim:mentionsumls-concept:C0043015lld:lifeskim
pubmed-article:9825789lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:9825789lifeskim:mentionsumls-concept:C0038317lld:lifeskim
pubmed-article:9825789lifeskim:mentionsumls-concept:C1720154lld:lifeskim
pubmed-article:9825789lifeskim:mentionsumls-concept:C0014282lld:lifeskim
pubmed-article:9825789pubmed:issue2lld:pubmed
pubmed-article:9825789pubmed:dateCreated1998-12-3lld:pubmed
pubmed-article:9825789pubmed:abstractTextData on injecting anabolic steroid users, within the national Unlinked Anonymous HIV Prevalence Monitoring Survey of injecting drug users (IDUs) were analysed to determine their risk of acquiring blood borne viruses. One hundred and forty-nine participants who had injected anabolic steroids in the previous month were identified from 1991-6, contributing 1.4% of all participation episodes in the survey. Rates of needle and syringe sharing by steroid users were low. Three of the 149 (2.0%) had anti-HBc and none had anti-HIV in their salivary specimens. The prevalence of anti-HBc in steroid injectors was significantly lower than in heroin injectors, 275/1509 (18%) (P < 0.001), or in amphetamine injectors, 28/239 (12%) (P < 0.001). The risk of blood borne virus transmission amongst these steroid injectors is low, probably due to hygienic use of injecting equipment and low levels of sharing. It is important to distinguish steroid injectors from other IDUs because they are a distinct group in terms of lifestyle and injecting practice.lld:pubmed
pubmed-article:9825789pubmed:languageenglld:pubmed
pubmed-article:9825789pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9825789pubmed:citationSubsetIMlld:pubmed
pubmed-article:9825789pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9825789pubmed:statusMEDLINElld:pubmed
pubmed-article:9825789pubmed:monthOctlld:pubmed
pubmed-article:9825789pubmed:issn0950-2688lld:pubmed
pubmed-article:9825789pubmed:authorpubmed-author:LewisK MKMlld:pubmed
pubmed-article:9825789pubmed:authorpubmed-author:ParryJ VJVlld:pubmed
pubmed-article:9825789pubmed:authorpubmed-author:GillO NONlld:pubmed
pubmed-article:9825789pubmed:authorpubmed-author:CrampinA CAClld:pubmed
pubmed-article:9825789pubmed:authorpubmed-author:HopeV DVDlld:pubmed
pubmed-article:9825789pubmed:authorpubmed-author:LamagniT LTLlld:pubmed
pubmed-article:9825789pubmed:authorpubmed-author:NewhamJ AJAlld:pubmed
pubmed-article:9825789pubmed:issnTypePrintlld:pubmed
pubmed-article:9825789pubmed:volume121lld:pubmed
pubmed-article:9825789pubmed:ownerNLMlld:pubmed
pubmed-article:9825789pubmed:authorsCompleteYlld:pubmed
pubmed-article:9825789pubmed:pagination381-6lld:pubmed
pubmed-article:9825789pubmed:dateRevised2010-3-3lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:meshHeadingpubmed-meshheading:9825789-...lld:pubmed
pubmed-article:9825789pubmed:year1998lld:pubmed
pubmed-article:9825789pubmed:articleTitleThe risk of infection with HIV and hepatitis B in individuals who inject steroids in England and Wales.lld:pubmed
pubmed-article:9825789pubmed:affiliationDepartment of Public Health and Epidemiology, King's College School of Medicine and Dentistry, London, UK.lld:pubmed
pubmed-article:9825789pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9825789pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed